Get the Stockscreener App
34.55
1.35%
0.46
Pre-market:
34.53
-0.02
-0.06%
Atricure Inc stock is traded at $34.55, with a volume of 730.59K.
It is up +1.35% in the last 24 hours and down -1.99% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$34.09
Open:
$34.19
24h Volume:
730.59K
Relative Volume:
1.55
Market Cap:
$1.72B
Revenue:
$499.95M
Net Income/Loss:
$-36.36M
P/E Ratio:
-44.87
EPS:
-0.77
Net Cash Flow:
$24.22M
1W Performance:
-7.96%
1M Performance:
-1.99%
6M Performance:
+15.51%
1Y Performance:
+4.13%
1-Day Range:
$33.76
$35.13
1-Week Range:
$30.93
$38.42
52-Week Range:
$28.29
$43.11
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
34.55 | 1.69B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
534.28 | 187.89B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
178.71 | 51.42B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
73.89 | 36.71B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
RMD
Resmed Inc
|
246.88 | 36.82B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
WST
West Pharmaceutical Services Inc
|
282.07 | 20.04B | 2.96B | 487.70M | 344.00M | 6.6758 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure, Inc. $ATRC Stake Raised by Nicholas Company Inc. - MarketBeat
What’s the recovery path for long term holders of AtriCure Inc.2025 Analyst Calls & Technical Pattern Alert System - newser.com
Is AtriCure Inc. stock near bottom after declineWeekly Profit Report & Long-Term Capital Growth Ideas - newser.com
Is AtriCure Inc. stock overvalued by current metrics2025 Market Outlook & Verified Swing Trading Watchlist - newser.com
AtriCure (ATRC) Is Down 8.0% After Raising 2025 Guidance and Reporting Narrower LossesHas The Bull Case Changed? - simplywall.st
Why AtriCure Inc. stock is recommended by analysts2025 Trading Recap & Intraday High Probability Setup Alerts - newser.com
AtriCure Inc. stock trendline breakdownTrade Performance Summary & Precise Swing Trade Alerts - newser.com
Does AtriCure Inc. qualify in momentum factor screeningTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Exit strategy if you’re trapped in AtriCure Inc.Bull Run & Stepwise Swing Trade Plans - newser.com
Intraday pattern recognizer results for AtriCure Inc.Weekly Profit Analysis & Stock Portfolio Risk Management - newser.com
How sustainable is AtriCure Inc. stock dividend payoutJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
AtriCure, Inc. (ATRC) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth - MSN
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
AtriCure’s BoxX-NoAF Trial: A Step Forward in Cardiac Surgery Innovation - MSN
AtriCure’s Earnings Call Highlights Robust Growth and Innovation - The Globe and Mail
AtriCure, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:ATRC) 2025-10-31 - Seeking Alpha
AtriCure’s HEAL-IST IDE Trial: A Promising Step in Treating Inappropriate Sinus Tachycardia - MSN
AtriCure (NASDAQ:ATRC) Sees Large Volume Increase on Strong Earnings - MarketBeat
Atricure (ATRC) Gets a Buy from Canaccord Genuity - The Globe and Mail
AtriCure (ATRC) Margin Miss Challenges Hopes for Near-Term Profitability Despite Strong Growth Forecasts - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
AtriCure Inc. stock trend forecastInsider Selling & Smart Allocation Stock Tips - newser.com
Analyzing drawdowns of AtriCure Inc. with statistical toolsMarket Performance Summary & Capital Protection Trade Alerts - newser.com
Why AtriCure Inc. stock is seen as undervaluedRate Cut & AI Optimized Trading Strategy Guides - newser.com
Canaccord Genuity raises AtriCure stock price target to $64 on strong Q3 results - Investing.com Nigeria
AtriCure stock maintains Buy rating at Needham following strong Q3 results - Investing.com Nigeria
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial - MedTech Intelligence
AtriCure stock maintains Buy rating at Needham following strong Q3 results By Investing.com - Investing.com South Africa
AtriCure stock rises as Citizens reiterates Market Outperform rating after strong Q3 - Investing.com UK
Is AtriCure Inc. stock trading near support levels2025 Top Decliners & AI Driven Stock Reports - newser.com
AtriCure, Inc. Reports Strong Q3 2025 Results - The Globe and Mail
Decoding AtriCure Inc (ATRC): A Strategic SWOT Insight - GuruFocus
AtriCure (NASDAQ:ATRC) Updates FY 2025 Earnings Guidance - MarketBeat
Canaccord Genuity Maintains AtriCure (ATRC) Buy Recommendation - Nasdaq
AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
AtriCure Inc (ATRC) Q3 2025 Earnings Call Highlights: Strong Rev - GuruFocus
AtriCure (ATRC) Q3 2025 Earnings Call Transcript - The Globe and Mail
AtriCure, Inc. SEC 10-Q Report - TradingView
[10-Q] AtriCure, Inc. Quarterly Earnings Report | ATRC SEC FilingForm 10-Q - Stock Titan
AtriCure (ATRC) Target Price Raised by Canaccord Genuity | ATRC Stock News - GuruFocus
AtriCure’s TRAC-AF Registry: A Closer Look at Ongoing Clinical Study - MSN
AtriCure Q3 2025 Earnings Call Transcript - MarketBeat
AtriCure earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.60%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):